Biodexa Pharmaceuticals Plc's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Biodexa Pharmaceuticals Plc's ROA in the fourth quarter of 2025?
Biodexa Pharmaceuticals Plc recorded a cumulative net loss of $-6 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -27.94%.

However, within the Healthcare sector 534 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2025 from to 4360.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	36.31 %	32.09 %	8.67 %	32.09 %	37.42 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-6	-6	-6	-6	-6
Return On Assets (TTM)	-27.94 %	-26.99 %	-29.02 %	-29.56 %	-32.01 %
BDRX's Total Ranking	# 4360	#	#	#	# 4641
Total Assets (TTM) in million	24	24	18	24	18
Seq. Total Assets Change	-0.49 %	34.47 %	-25.63 %	36.98 %	-3.57 %
Seq. Net Income Change	-	-	-	-	-

BDRX's 5 Years Annual ROA >> Back to BDRX Management Effectiveness >> Compare BDRX ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 217
Sector	# 535
Overall	# 4322

Return On Assets Statistics
High	Average	Low
-24.6 %	-69.82 %	-165.44 %
(Dec 31 2019)		(Dec 31 2020)

Financial Statements
Biodexa Pharmaceuticals Plc's Assets	$ 24 million	BDRX's Balance sheet
Biodexa Pharmaceuticals Plc's Income	$ -6 million	Quarterly BDRX's Income Statement
BDRX's Income by Division		See BDRX's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	23 %	40.2 %	90.81 %	-68.31 %	-32.19 %
Total Assets in million	18	15	11	6	17
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-6	-6	-7	-8	-5
Annual Return On Assets	-35.12 %	-38.76 %	-67.15 %	-138.57 %	-31.32 %

BDRX's 5 Years Annual ROA >> Back to BDRX Management Effectiveness >> Compare BDRX ROA to its Competitors

More Return On Assets Ratios
BDRX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
BDRX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for BDRX's Competitors
Subscribers only: Roa for Biodexa Pharmaceuticals Plc's Suppliers
Subscribers only: Return On Assets for BDRX's Customers

You may also want to know
BDRX's Roi	BDRX's Inventory Turnover Ratio	BDRX's Growth Rates	BDRX's Dividend Comparisons
	BDRX's Profitability Ratios	BDRX's Asset Turnover Ratio	BDRX's Dividend Growth
BDRX's Roe	BDRX's Valuation Ratios	BDRX's Financial Strength Ratios	BDRX's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-07-07T09:28:23+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.